Combination therapy with GLP‐1 RAs and SGLT2 inhibitors is recommended by the ADA and European Association for the Study of Diabetes 2018 consensus report for persons with T2D and atherosclerotic CVD and/or CKD who are not meeting their glycated hemoglobin targets with other medication [114]. This evidence concerns the gene SLC5A2 and chronic kidney disease.